Evidence map›Paper›PMID 42738906›Full record

ArticleCells2026

Differential Modulation of the DR5-JNK-PD-L1 Signaling Axis by TRiC/CCT Subunits CCT7 and CCT2 Shapes Tumor Immune Evasion in Lung Adenocarcinoma.

Hsin-Wei Jen, Hsiang-Ling Ho, Teh-Ying Chou

Abstract read
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hsin-Wei JenTranslational Medicine Center, Department of Research, Shin Kong Wu Ho-Su Memorial Hospital, Taipei 111, Taiwan.
Hsiang-Ling HoDepartment of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Teh-Ying ChouDepartment of Pathology and Laboratory Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei 111, Taiwan.

Funding

National Science and Technology Council 112-2320-B-038-047-MY3
6 · The paper itself

Abstract

While the chaperonin-containing TCP-1 (CCT) complex is essential for proteostasis, the distinct roles of individual subunits in tumor immune regulation remain unclear. Here, we identify CCT7 as a previously unrecognized regulator of immune evasion in lung adenocarcinoma (LUAD). Integrative analyses of TCGA and GEO cohorts revealed that CCT7 is markedly upregulated in LUAD and is associated with poor patient prognosis. Functional studies demonstrated that CCT7 knockdown inhibited tumor cell proliferation and migration and enhanced cisplatin-induced apoptosis, yet paradoxically impaired T-cell activation. Mechanistically, transcriptomic and biochemical analyses revealed that CCT7 depletion activated the DR5-MKK4-JNK-c-Jun signaling cascade, resulting in the transcriptional upregulation of PD-L1. Disruption of DR5 or JNK signaling effectively abrogated PD-L1 induction. In contrast, CCT2 depletion exerted the opposite effect by suppressing the DR5-JNK-c-Jun-PD-L1 signaling axis and enhancing T-cell activation. Collectively, these findings reveal unexpected functional divergence among TRiC/CCT subunits and identify the CCT7-DR5-JNK-c-Jun signaling axis as a previously unrecognized mechanism regulating PD-L1-mediated immune evasion, highlighting the potential therapeutic relevance of this signaling axis in LUAD.

Indexed as

Adenocarcinoma of LungB7-H1 AntigenChaperonin Containing TCP-1Lung NeoplasmsTumor EscapeAnimalsApoptosisCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansJNK Mitogen-Activated Protein KinasesSignal TransductionT-LymphocytesB7-H1 AntigenCD274 protein, humanChaperonin Containing TCP-1JNK Mitogen-Activated Protein KinasesCCT2CCT7c-JunDR5JNKPD-L1

Identifiers

PMID42738906
PMCPMC13565191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.